Track safety of Xeljanz XR in Korea
Part of Bones, joints & muscles, Immune system & allergy clinical trials.
This study collects real-world safety information about Xeljanz XR after it has been approved. It includes people with certain immune-related joint diseases and checks for side effects in everyday use.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18+) and using Xeljanz XR for an approved condition (like rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis).
- Your doctor is prescribing Xeljanz XR for you because prior treatments didn’t work or you couldn’t tolerate them.
- If you’re switching from Xeljanz 5 mg to Xeljanz XR, you can still join.
- You (or your legal representative) can sign and date the informed consent form.
- You do not have a history of allergy or serious reaction to any ingredients in Xeljanz XR.
- You do not have certain infection or blood-count problems, active tuberculosis, or severe liver problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is collecting real-world information about how Xeljanz (tofacitinib) is used and how well it works in children with juvenile idiopathic arthritis. It may help improve how the medicine is used safely in everyday care.
This study tracks Korean patients already taking Jyseleca for rheumatoid arthritis or ulcerative colitis, making sure it's safe and working as expected. It's not testing a new drug, just watching how patients do over time.
This study follows people with moderately to severely active ulcerative colitis who are taking the medication tofacitinib (Xeljanz). It aims to track any safety concerns in a real-world setting, using information already collected in a European registry (UR-CARE).
This early-stage study tests a new injectable medicine (KT501) for people with moderate to severe rheumatoid arthritis who have not responded well enough to other treatments and have specific antibodies in their blood. It aims to see how safe and well-tolerated the drug is.
This study tests a new medication called AZD1163 for people with rheumatoid arthritis (RA) that hasn't responded well enough to standard treatments. It aims to see if the drug can safely reduce joint swelling and pain.
This trial tests taking a JAK inhibitor (a type of pill that helps calm inflammation in rheumatoid arthritis) by mouth. It aims to see how well it works and if it's safe for people with RA who need this kind of medicine.
Hear when a new Active Moderate to Severe Rheumatoid Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.